Indian company can now make Spinal Muscular Atrophy drug, High Court cites public interest
The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...
Delhi HC tells Natco Pharma to pause launch of generic version of Risdiplam
Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...
Pharmabiz2d
Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy
Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...
Delhi HC restrains Natco Pharma from launching generic of Roche's rare disease drug
"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...
HC allows Natco Pharma to make Swiss firm Roche’s spinal muscular atrophy drug in public interest
The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.
Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent
The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...
The Week5d
How Delhi High Court's latest verdict is a boon for spinal muscular atrophy patients
A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...
Delhi HC denies interim injunction on Roche rare disease drug, opening the door for generic versions
Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...
Pharmabiz4d
Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi
Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
Novartis announces results from Phase III program for OAV101 IT
Novartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene ...
Bar and Bench6d
Delhi High Court allows Natco to make Roche's spinal muscular atrophy drug in public interest
The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...